WOMEN 'S HEALTH AND MENOPAUSE : - National Heart, Lung ...

101 Hulley S, Grady D, Bush T, et al. Randomized trial
of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal
women. Heart and Estrogen/progestin Replacement
Study (HERS) Research Group. JAMA
1998;280(7):605—13.
102 Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K.
Medroxyprogesterone interferes with ovarian
steroid protection against coronary vasospasm.
Nat Med 1997;3(3):324–7.
103 Rosano GM, Webb CM, Chierchia S, et al. Natural
progesterone, but not medroxyprogesterone acetate,
enhances the beneficial effect of estrogen on exercise-induced
myocardial ischemia in postmenopausal
women. J Am Coll Cardiol
2000;36(7):2154–9.
104 Herrington DM, Reboussin DM, Brosnihan KB, et al.
Effects of estrogen replacement on the progression
of coronary-artery atherosclerosis. N Engl J Med
2000;343(8):522–9.
105 Fisher B, Costantino JP, Wickerham DL, et al.
Tamoxifen for prevention of breast cancer: report
of the National Surgical Adjuvant Breast and
Bowel Project P-1 Study. J Natl Cancer Inst
1998;90(18):1371–88.
106 Kuiper GG, Lemmen JG, Carlsson B, et al.
Interaction of estrogenic chemicals and phytoestrogens
with estrogen receptor beta. Endocrinology
1998;139(10):4252–63.
107 Jordan VC. Designer estrogens. Sci Am
1998;279(4):60–7.
108 Shewmon DA, Stock JL, Abusamra LC, Kristan MA,
Baker S, Heiniluoma KM. Tamoxifen decreases
lipoprotein (a) in patients with breast cancer.
Metabolism 1994;43(5):531–2.
109 Walsh BW, Kuller LH, Wild RA, et al. Effects of
raloxifene on serum lipids and coagulation factors
in healthy postmenopausal women. JAMA
1998;279(18):1445–51.
110 Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects
of raloxifene on bone mineral density, serum cholesterol
concentrations, and uterine endometrium in
postmenopausal women. N Engl J Med
1997;337(23):1641–7.
111 Miettinen M, Turpeinen O, Karvonen MJ, Elosuo R,
Paavilainen E. Effect of cholesterol-lowering diet
on mortality from coronary heart-disease and other
causes. A twelve-year clinical trial in men and
women. Lancet 1972;2(7782):835–8.
112 Rutqvist LE, Mattsson A. Cardiac and thromboembolic
morbidity among postmenopausal women
with early-stage breast cancer in a randomized trial
of adjuvant tamoxifen. The Stockholm Breast
Cancer Study Group. J Natl Cancer Inst
1993;85(17):1398–406.
113 McDonald CC, Alexander FE, Whyte BW, Forrest
AP, Stewart HJ. Cardiac and vascular morbidity in
women receiving adjuvant tamoxifen for breast
cancer in a randomised trial. The Scottish Cancer
Trials Breast Group. BMJ 1995;311(7011):977–80.
114 Costantino JP, Kuller LH, Ives DG, Fisher B,
Dignam J. Coronary heart disease mortality and
adjuvant tamoxifen therapy. J Natl Cancer Inst
1997;89(11):776–82.
115 Barrett-Connor E, Wenger NK, Grady D, et al.
Coronary heart disease in women, randomized clinical
trials, HERS and RUTH (editorial). Maturitas
1998;31:1–7.
116 Clarkson TB, Anthony MS, Jerome CP. Lack of
effect of raloxifene on coronary artery atherosclerosis
of postmenopausal monkeys. J Clin
Endocrinol Metab 1998;83(3):721–6.
117 Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF,
Christiansen C. Raloxifene inhibits aortic accumulation
of cholesterol in ovariectomized, cholesterolfed
rabbits. Circulation 1997;96(6):1964–9.
118 Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene
acutely relaxes rabbit coronary arteries in vitro by
an estrogen receptor-dependent and nitric oxidedependent
mechanism. Circulation
1999;100(10):1095–101.
119 Revelli A, Soldati G, Costamagna C, et al. Follicular
fluid proteins stimulate nitric oxide (NO) synthesis
in human sperm: a possible role for NO in acrosomal
reaction. J Cell Physiol 1999;178(1):85–92.
120 Revelli A, Tesarik J, Massobrio M. Nongenomic
effects of neurosteroids (review). Gynecol
Endocrinol 1998;12(1):61–7.
173